Heart, Lung, Blood and Sleep Disorders
Last data update: Jun 22, 2024 . (Total: 47575 Documents since 2020)
Records 1-30 (of 50 Records) |
Query Trace: Pericarditis[original query] |
---|
The role of colchicine in the management of COVID-19: a Meta-analysis. Elshiwy Kholoud, et al. BMC pulmonary medicine 2024 0 0. (1) 190 ![]() |
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial. Dayan Gustavo H, et al. The Lancet. Respiratory medicine 2023 0 0. ![]() ![]() ![]() |
Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis. Abdallah Alami et al. BMJ Open 2023 6 (6) e065687 ![]() ![]()
Seven studies met the inclusion criteria, of which six were included in the quantitative synthesis. Our meta-analysis indicates that within 30-day follow-up period, vaccinated individuals were twice as likely to develop myo/pericarditis in the absence of SARS-CoV-2 infection compared to unvaccinated individuals, with a rate ratio of 2.05 (95% CI 1.49-2.82). Although the absolute number of observed myo/pericarditis cases remains quite low, a higher risk was detected in those who received mRNA COVID-19 vaccinations compared with unvaccinated individuals in the absence of SARS-CoV-2 infection.
|
The Evolving Etiological and Epidemiological Portrait of Pericardial Disease. Reddy Prajwal, et al. The Canadian journal of cardiology 2023 0 0. ![]() |
Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada SA Buchan et al, JAMA Pediatrics, February 27, 2023 ![]()
In this population-based cohort study of 1.65 million doses of BNT162b2 vaccinations among adolescents in Ontario, Canada, there were 77 adolescents with myocarditis or pericarditis after vaccination and a higher reported incidence among adolescents aged 16 to 17 years vs 12 to 15 years and among those aged 16 to 17 years with a shorter interval between doses. Overall, many of the cases of myocarditis and pericarditis were mild, and the adolescents required either no treatment or were treated conservatively with nonsteroidal anti-inflammatory drugs.
|
A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink. Yih W Katherine, et al. Vaccine 2022 0 0. ![]() ![]() |
Results of safety monitoring of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in U.S. children aged 5-17 years M Hu et al, MEDRXIV, October 30, 2022 ![]()
The study included over 3 million enrollees aged 5-17 years with BNT162b2 COVID-19 vaccination through mid-2022 in three commercial claims databases.
Consistent with published literature, our near-real time monitoring identified a signal for only myocarditis/pericarditis following BNT162b2 COVID-19 vaccination in children aged 12-17 years. This method is intended for early detection of safety signals. Our results are reassuring of the safety of the vaccine, and the potential benefits of vaccination outweigh the risks.
|
Risk of Myocarditis and Pericarditis Following Coronavirus Disease 2019 Messenger RNA Vaccination - A Nationwide Study WJ Su et al, MEDRXIV, October 13, 2022 ![]()
Here we present nationwide data of mRNA COVID-19 vaccination-associated myocarditis and pericarditis in Taiwan. Methods. Data on adverse events of myocarditis/pericarditis were from the Taiwan Vaccine Adverse Events Reporting System between March 22, 2021, and February 9, 2022. The rates according to sex, age, and vaccine type were calculated. We found that myocarditis and pericarditis are rare following mRNA vaccination, with higher risk occurring in young males after the second dose.
|
Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system. Chen Congqin, et al. Frontiers in immunology 2022 0 0. 938322 ![]() ![]() |
Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study. Massari Marco, et al. PLoS medicine 2022 0 0. (7) e1004056 ![]() ![]() ![]() |
Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study. Andersson Niklas Worm et al. BMJ (Clinical research ed.) 2022 7 e070483 ![]() ![]()
Heterologous primary and booster covid-19 vaccine schedules of ChAdOx1-S priming and mRNA booster doses as both second and third doses were not associated with increased risk of serious adverse events compared with homologous mRNA vaccine schedules. These results are reassuring but given the rarity of some of the adverse events, associations cannot be excluded.
|
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. Pillay Jennifer et al. BMJ (Clinical research ed.) 2022 7 e069445 ![]() ![]() ![]() ![]()
The findings indicate that adolescent and young adult men are at the highest risk of myocarditis after mRNA vaccination. Use of a Pfizer vaccine over a Moderna vaccine and waiting for more than 30 days between doses might be preferred for this population. Incidence of myocarditis in children aged 5-11 years is very rare but certainty was low. Data for clinical risk factors were very limited. A clinical course of mRNA related myocarditis appeared to be benign, although longer term follow-up data were limited. Prospective studies with appropriate testing (eg, biopsy and tissue morphology) will enhance understanding of mechanism.
|
Myocarditis and pericarditis risk after covid-19 vaccination BMJ Editorial, July 13, 2022 ![]()
Despite the large numbers of studies reviewed, the overall certainty of the conclusions remains low, with a very wide range reported for myocarditis incidence. That we are now more than a year and a half into mass mRNA vaccination and still do not have strong certainty about the incidence of this clinically important outcome is disappointing. Because these events are rare, making precise estimates is difficult.
|
Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases HL Wong et al, The Lancet, June 11, 2022 ![]() ![]()
A total of 411 myocarditis or pericarditis, or both, events were observed among 15?148?369 people aged 18–64 years who received 16?912?716 doses of BNT162b2 and 10?631?554 doses of mRNA-1273. Among men aged 18–25 years, the pooled incidence rate was highest after the second dose, at 1·71 (95% CI 1·31 to 2·23) per 100?000 person-days for BNT162b2 and 2·17 (1·55 to 3·04) per 100?000 person-days for mRNA-1273. The pooled IRR in the head-to-head comparison of the two mRNA vaccines was 1·43 (95% CI 0·88 to 2·34), with an excess risk of 27·80 per million doses (–21·88 to 77·48) in mRNA-1273 recipients compared with BNT162b2.
|
A pharmacoepidemiological study of myocarditis and pericarditis following mRNA COVID-19 vaccination in Europe J Tome et al, MEDRXIV, May 28, 2022 ![]() |
Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age. Creech C Buddy et al. The New England journal of medicine 2022 5 ![]() ![]() ![]()
Vaccination of children to prevent coronavirus disease 2019 (Covid-19) is an urgent public health need. The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in children 6 to 11 years of age are unknown. Part 1 of this ongoing phase 2–3 trial was open label for dose selection; part 2 was an observer-blinded, placebo-controlled expansion evaluation of the selected dose. In part 2, we randomly assigned children (6 to 11 years of age) in a 3:1 ratio to receive two injections of mRNA-1273 (50 µg each) or placebo, administered 28 days apart. The primary objectives were evaluation of the safety of the vaccine in children and the noninferiority of the immune response in these children to that in young adults (18 to 25 years of age) in a related phase 3 trial. We found that two 50-µg doses of the mRNA-1273 vaccine were found to be safe and effective in inducing immune responses and preventing Covid-19 in children 6 to 11 years of age; these responses were noninferior to those in young adults.
|
Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination. Mengesha Bethlehem, et al. Vaccines 2022 0 0. (4) ![]() ![]() |
Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination S Lane et al, MEDRXIV, April 19, 2022 ![]() |
Reports of myocarditis and pericarditis following mRNA COVID-19 vaccines: A systematic review of spontaneously reported data from the UK, Europe, and the US and of the literature S Lane et al, MEDRXIV, April 8, 2022 ![]() ![]() |
FULMINANT MYOCARDITIS IN A PATIENT WITH A LUNG ADENOCARCINOMA AFTER THE THIRD DOSE OF MODERN COVID-19 VACCINE. A CASE REPORT AND LITERATURE REVIEW. Brage Eduardo Terán, et al. Current problems in cancer. Case reports 2022 0 0. 100153 ![]() |
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. Moreira Edson D et al. The New England journal of medicine 2022 3 ![]() ![]()
In this ongoing, placebo-controlled, randomized, phase 3 trial, we assigned participants who had received two 30-µg doses of the BNT162b2 vaccine at least 6 months earlier to be injected with a third dose of the BNT162b2 vaccine or with placebo. We assessed vaccine safety and efficacy against Covid-19 starting 7 days after the third dose. A third dose of the BNT162b2 vaccine administered a median of 10.8 months after the second dose provided 95.3% efficacy against Covid-19 as compared with two doses of the BNT162b2 vaccine during a median follow-up of 2.5 months.
|
Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. Salleh Mohd Zulkifli, et al. PeerJ 2022 0 0. e13083 ![]() ![]() ![]() ![]() |
Safety of the BNT162b2 mRNA COVID-19 vaccine in patients with familial Mediterranean fever. Shechtman Liran, et al. Rheumatology (Oxford, England) 2022 0 0. ![]() ![]() |
Myocarditis and pericarditis following mRNA COVID-19 vaccination in younger patients: is there a shared thread? Mormile Raffaella, et al. Expert review of cardiovascular therapy 2022 0 0. 1-4 ![]() |
Myocarditis and Pericarditis following COVID-19 Vaccination: Evidence Syntheses on Incidence, Risk Factors, Natural History, and Hypothesized Mechanisms J Pillay et al, MEDRXIV, March 1, 2022 ![]()
Adolescent and young adult males are at the highest risk of myocarditis after mRNA vaccination. Pfizer over Moderna and waiting more than 30 days between doses may be preferred for this population. Incidence of myocarditis in children aged 5-11 may be very rare but certainty was low. Data on clinical risk factors was very limited. Clinical course of mRNA related myocarditis appears to be benign although longer term follow-up data is limited.
|
Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy: a multi-database, self-controlled case series study M Massari et al, MEDRXIV, February 8, 2022 ![]() ![]() |
Colchicine Against SARS-CoV-2 Infection: What is the Evidence? Drosos Alexandros A, et al. Rheumatology and therapy 2022 0 0. ![]() ![]() |
Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review. Zhang Fan-Shun, et al. Acta pharmacologica Sinica 2022 0 0. ![]() ![]() |
Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection M Patone et al, December 14, 2021 ![]()
We found increased risks of myocarditis associated with the first dose of ChAdOx1 and BNT162b2 vaccines and the first and second doses of the mRNA-1273 vaccine over the 1–28 days postvaccination period, and after a SARS-CoV-2 positive test. We estimated an extra two (95% confidence interval (CI) 0, 3), one (95% CI 0, 2) and six (95% CI 2, 8) myocarditis events per 1?million people vaccinated with ChAdOx1, BNT162b2 and mRNA-1273, respectively, in the 28?days following a first dose and an extra ten (95% CI 7, 11) myocarditis events per 1?million vaccinated in the 28?days after a second dose of mRNA-1273. This compares with an extra 40 (95% CI 38, 41) myocarditis events per 1?million patients in the 28?days following a SARS-CoV-2 positive test.
|
Systematic review of cardiac adverse effects in children and young people un-der 18 years of age after SARS-CoV-2 vaccination J Cruz et al, MEDRXIV, December 7, 2021 ![]()
There were 1129 reports of myocarditis and 358 reports of pericarditis from across the USA and EU/EEA. The VAERS reporting rate per million for myocarditis was 12.4 for boys and 1.4 for girls after the first dose, and 49.6 for boys and 6.1 for girls after the second dose. There was a marked trend for VAERS reporting to be highest soon after initiation of the vaccine schedule, suggesting reporting bias. Conclusions Cardiac adverse effects are very rare after mRNA vaccination for COVID-19 in CYP <18 years. The great majority of cases are mild and self-limiting without significant treatment. No data are yet available on children under 12 years.
|
Disclaimer: Articles listed in the Public Health
Knowledge Base are selected by the CDC Office of Public Health
Genomics to provide current awareness of the literature and news.
Inclusion in the update does not necessarily represent the views of
the Centers for Disease Control and Prevention nor does it imply
endorsement of the article's methods or findings. CDC and DHHS assume
no responsibility for the factual accuracy of the items presented. The
selection, omission, or content of items does not imply any
endorsement or other position taken by CDC or DHHS. Opinion, findings
and conclusions expressed by the original authors of items included in
the update, or persons quoted therein, are strictly their own and are
in no way meant to represent the opinion or views of CDC or DHHS.
References to publications, news sources, and non-CDC Websites are
provided solely for informational purposes and do not imply
endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:Jun 21, 2024
- Content source: